Aquatic Capital Management LLC Sells 1,671 Shares of Envista Holdings Co. (NYSE:NVST)

Aquatic Capital Management LLC lessened its holdings in shares of Envista Holdings Co. (NYSE:NVST) by 8.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,529 shares of the company’s stock after selling 1,671 shares during the quarter. Aquatic Capital Management LLC’s holdings in Envista were worth $338,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Thurston Springer Miller Herd & Titak Inc. bought a new position in Envista in the 4th quarter worth $53,000. Lecap Asset Management Ltd. purchased a new stake in Envista in the fourth quarter worth about $281,000. Hantz Financial Services Inc. boosted its position in Envista by 146.6% during the 4th quarter. Hantz Financial Services Inc. now owns 110,489 shares of the company’s stock valued at $2,131,000 after acquiring an additional 65,679 shares in the last quarter. Norges Bank purchased a new position in shares of Envista during the 4th quarter worth approximately $38,052,000. Finally, Natixis Advisors LLC raised its position in shares of Envista by 1.8% in the 4th quarter. Natixis Advisors LLC now owns 106,652 shares of the company’s stock worth $2,057,000 after acquiring an additional 1,845 shares in the last quarter.

Envista Price Performance

NYSE NVST opened at $16.97 on Friday. Envista Holdings Co. has a one year low of $14.22 and a one year high of $23.00. The stock has a 50-day moving average of $16.73 and a 200 day moving average of $19.05. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. The company has a market capitalization of $2.88 billion, a price-to-earnings ratio of -2.61, a PEG ratio of 1.27 and a beta of 1.12.

Envista (NYSE:NVST) last announced its quarterly earnings results on Thursday, May 1st. The company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.04. The firm had revenue of $616.90 million during the quarter, compared to analyst estimates of $608.17 million. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. The business’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.26 earnings per share. On average, sell-side analysts forecast that Envista Holdings Co. will post 1 EPS for the current year.

Analyst Ratings Changes

NVST has been the topic of several recent research reports. JPMorgan Chase & Co. reduced their price target on Envista from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. Bank of America reduced their target price on shares of Envista from $26.00 to $23.00 and set a “buy” rating on the stock in a research report on Tuesday. Jefferies Financial Group lifted their price target on shares of Envista from $20.00 to $22.00 and gave the company a “hold” rating in a research report on Thursday, January 23rd. New Street Research set a $19.00 price objective on shares of Envista in a report on Thursday, March 6th. Finally, UBS Group lowered their target price on shares of Envista from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Monday, March 10th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $20.18.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.